Major R&D Pipeline: 3ADCs
Major R&D Pipeline: Alpha
Daiichi-Sankyo
Phase 1
B7-H3-directed ADC
DS-7300 (JP/US)
Solid tumors
DS-6157 (JP/US)
GPR20-directed ADC
GIST
DS-6000 (US)
CDH6-directed ADC
Renal cell carcinoma, ovarian cancer
DS-1055 (JP/US)
Anti-GARP antibody
Solid tumors
DS-1211 (US)
DS-3201 (JP/US)
EZH1/2 inhibitor
Non-Hodgkin's lymphomas
PLX2853 (US)
BET inhibitor
AML
PLX2853 (US)
BET inhibitor
Solid tumor
PLX2853 (US)
BET inhibitor
DS-3201 (JP)
Phase 2
EZH1/2 inhibitor
ATL/L
DS-3201 (JP/US/EU/Asia)
EZH1/2 inhibitor
PTCL
DS-1001 (JP)
Mutant IDH1 inhibitor
Glioma
DS-5141 (JP)
ENA oligonucleotide
Gynecologic neoplasms, ovarian cancer DMD
PLX2853 (US)
Phase 3
Quizartinib (JP/US/EU/Asia)
FLT3 inhibitor
1L AML
Pexidartinib (JP/Asia)
CSF-1/KIT/FLT3 inhibitor
Tenosynovial giant cell tumor
Minnebro (JP)
MR blocker
Diabetic nephropathy
VN-0102/JVC-001 (JP)
Measles mumps rubella combined
vaccine
Tarlige (JP)
As of July 2021
a28 Ligands
Submitted
Central neuropathic pain
Lixiana (JP)
FXa inhibitor
AF in the very elderly
Efient (JP)
ADP receptor inhibitor
Ischemic stroke
VN-0107/MEDI3250 (JP)
Live attenuated influenza vaccine nasal
spray
TNAP inhibitor
Pseudoxanthoma elasticum
DS-6016 (JP)
Anti-ALK2 antibody
DS-5670 (JP)
mRNA vaccine
BET inhibitor
Prostate cancer
DS-1594 (US)
Menin-MLL binding inhibitor
VN-0200 (JP)
Fibrodysplasia Ossificans Progressiva AML, ALL
RS virus vaccine
COVID-19
Oncology
RS virus
Specialty medicine
Vaccine
AF: atrial fibrillation, ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, DMD: Duchenne muscular dystrophy, GIST: gastrointestinal stromal tumor,
PTCL: peripheral T-cell lymphoma
: project in oncology that is planned to be submitted for approval based on the results of phase 2 trials : SAKIGAKE Designation (JP) Orphan drug designation (JP/US/Europe)
36View entire presentation